Candel Therapeutics (CADL) has released an update.
Candel Therapeutics, Inc. has achieved a significant milestone with the FDA’s Fast Track Designation for its pioneering treatment, CAN-3110, targeting recurrent high-grade glioma. This innovative therapy, harnessing the power of an oncolytic virus, aims to enhance patients’ survival, marking a promising advancement in the fight against this aggressive brain cancer. Investors and healthcare watchers are eyeing this development as a potentially transformative step for the company’s future prospects.
For further insights into CADL stock, check out TipRanks’ Stock Analysis page.
